-
2.5 billion anti-ED drugs!
Time of Update: 2022-05-15
entered the stage of administrative approval for the Sildenafil Citrate Orally Disintegrating Tablets, which were reported as imitation Category 4 .
Since the beginning of this year, Kelun Pharmaceutical has approved 5 products for the market, of which 3 are the first in China .
-
Ministry of Finance: There are new requirements for purchasing equipment, affecting CT, MRI, DSA...
Time of Update: 2022-05-15
Earlier, the "Administrative Measures for Government Procurement of Imported Products by Budget Units" issued by the Shaanxi Provincial Health and Health Commission also clarified that if each unit needs to purchase imported equipment for medical treatment, teaching and scientific research, it should meet one of the following conditions: 1.
-
National Development and Reform Commission: Strive to build national regional medical centers to cover all provinces by the end of the year
Time of Update: 2022-05-15
Give priority to the role of the planned national medical centers and national regional medical centers, give full play to the role of key hospitals under ministries and commissions, and provinces (cities), and encourage other high-level hospitals to participate in the task of exporting hospitals .
-
"Jianzhi" $8 billion Erye Pharmaceutical Rivaroxaban Tablets Enters Administrative Approval Stage
Time of Update: 2022-05-15
com, global sales of rivaroxaban in 2021 will exceed 8 billion US dollars; terminal sales in Chinese public medical institutions will exceed 3 billion yuan in 2020, with a year-on-year increase of 56.
2021H1 China's public medical institutions' terminal antithrombotic drug products TOP5 Source: Minet.
-
95 exclusive proprietary Chinese medicines are on display!
Time of Update: 2022-05-15
In recent years, sales of Chinese patent medicines in physical pharmacies in Chinese cities and online pharmacies in China (unit: 100 million yuan) Source: Minet Database Over 20 billion market!
-
Chongqing Yaoyou, Lepu... Ranked in the TOP20 of online pharmacy brands of liver disease chemical drugs
Time of Update: 2022-05-15
2021 Chinese online pharmacy terminal liver disease treatment chemical drug brand TOP20 Source: Minenet China online pharmacy chemical drug terminal competition pattern Among the commonly used antiviral drugs, China's diagnosis and treatment guidelines include entecavir and tenofovir disoproxil as hepatitis B treatment The first choice, and tenofovir alafenamide is the first choice internationally .
-
The profits of leading machinery companies are public: Medtronic, Mindray, Weigao, Abbott...
Time of Update: 2022-05-15
192 billion yuan; tumor prevention and control business achieved revenue of 380 million yuan, a year-on-year increase of 8.
62%; the medical terminal business achieved revenue of 700 million yuan, a year-on-year increase of 21.
-
A pharmacy was fined 1.25 million!
Time of Update: 2022-05-15
25 million yuan Recently, the State Food and Drug Administration announced 5 typical cases of special drug safety rectification, in which a chain pharmacy was fined 1.
-
The Medical Insurance Bureau issued a notice that there have been new changes in the marketing model of machinery companies
Time of Update: 2022-05-15
The DRG and DIP have not been settled, and the APG has risen again. . . A few days ago, the Zhejiang Provincial Medical Insurance Bureau issued a notice on the "Three-Year Action Plan for Comprehens
-
The reform of medical insurance further promotes the pharmaceutical industry to respond to the trend
Time of Update: 2022-05-15
On January 28, 2021, the General Office of the State Council issued "Opinions on Promoting the Normalization and Institutionalization of the Centralized Procurement of Medicines with Volume"; on June 4 of the same year, eight departments including the National Medical Insurance Bureau issued the "Guiding Opinions on Carrying out the Centralized Procurement and Use of High-value Medical Consumables Organized by the State" .
-
The price of Chinese patent medicine e-commerce platform has risen on the consumer side and the production side...
Time of Update: 2022-05-15
The rise in the price of Chinese patent medicines is due to the tight supply of social demand on the one hand, and the impact of the increase in the cost of production raw materials on the other hand.
-
The syllabus, application requirements and examination time of the licensed pharmacist examination have changed
Time of Update: 2022-05-15
In addition, at the beginning of last year, the General Office of the Ministry of Human Resources and Social Security formulated and issued the "Procedures for the Examination of Professional Qualification Examinations for Professional and Technical Personnel" (hereinafter referred to as the "Regulations"), and the examination of licensed pharmacists has become more standardized .
-
30 novel coronavirus antigen detection reagents have been approved by the State Food and Drug Administration
Time of Update: 2022-05-15
On April 27, the State Food and Drug Administration issued an announcement stating that it re-examined and approved a new coronavirus antigen detection reagent product, specifically the new coronavirus (2019-nCoV) antigen detection kit (latex) of Wuhan Shengzhiyuan Biotechnology Co.
-
Generic drug market continues to grow, localized production is in the ascendant
Time of Update: 2022-05-15
Most clinical drugs rely on imports According to statistics, there are about 400 drug manufacturers in sub-Saharan Africa, mainly located in South Africa, Nigeria, Kenya, Ghana, Ethiopia and other countries, of which the number of API manufacturers is very small.
-
Over 60% of the 73 overseas new drugs urgently needed for clinical use have been approved in China
Time of Update: 2022-05-15
A reporter from the Beijing News sorted out the data based on the Dingxiangyuan Insight database and public information and found that in the three batches of lists, 46 drugs have been approved in China, and metabolic diseases, tumors, and immune system diseases are relatively concentrated treatment areas .
-
Coron will win the $1.5 billion big variety!
Time of Update: 2022-05-15
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of Class 3 Sodium Glucose Injection, which is the second domestic company .
According to the first quarterly report of 2022, Kelun Pharmaceutical's net profit increased by 66.
-
Cases of severe acute hepatitis of unknown etiology in children continue to increase in Europe
Time of Update: 2022-05-15
(Headquarters reporter Hao Xiaoli) On April 28, local time, the European Centre for Disease Control and Prevention issued a statement that, as of April 20, 111 cases of severe acute hepatitis of unknown etiology had been identified in the UK as of April 20, after the UK first reported an increase in cases of severe acute hepatitis of unknown etiology among healthy children on April 5.
-
Xiebai relies on wild resources, and the market outlook is expected to rise slowly!
Time of Update: 2022-05-15
To sum up, as of now, the new output of Xiebai is limited, and the labor cost of harvesting and processing has increased, so the market price may rise in the future .
-
44 centralized collection varieties began to renew contracts with over one billion large varieties to choose between advance and retreat
Time of Update: 2022-05-15
From the perspective of terminal data, the market share of this large variety is being reshaped: the domestic market of parecoxib continues to expand, and the terminal sales of Chinese public medical institutions in 2020 will exceed 2 billion yuan, a year-on-year increase of 10.
-
Grasp the new blue ocean of the big health industry to promote economic growth and overtake
Time of Update: 2022-05-15
Since March 2022, a new round of COVID-19 has spread, and China's economic development has been greatly impacted, greatly increasing the downside risks of the macro economy . Coordinating and balan
